Chemical structure of molecule LYC-55716 Cintirorgon

oral ROR_ nuclear receptor agonist

450 mg BID, phase I/II, cancer

from change in MoA of ROR_ antagonist + opt.

Journal of Medicinal Chemistry


The Lycera ROR gamma agonist, cintirorgon (LYC-55716), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.